Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
DERM US and EU Validation Study
NCT05126173 · View on ClinicalTrials.gov ↗
Study Summary
This study aims establish the effectiveness of Image Analysing Algorithm (DERM) to identify melanoma, Squamous Cell Carcinoma (SCC) and Basal Cell Carcinoma (BCC) when used to analyse dermoscopic images of skin lesions within the US and European population.
Conditions Studied
Interventions
- DEVICE Deep Ensemble for the Recognition of Malignancy (DERM)
Study Locations (16)
Other
- Universitaria Di Bologna — Bologna
- Dermatology University of Florence — Florence
- Università degli Studi di Modena e Reggio Emilia — Modena
- University of Campania — Naples
- Università del Piemonte Orientale — Novara
- UOSD Dermatology Oncology — Roma
Florida
- Vista Health Research, LLC — Miami
- Dorisca Research Consulting, LLC — Miami
Massachusetts
- ALLCUTIS Research, LLC — Beverly
- Allcutis Research — Methuen
California
- Stanford university — Redwood City
Illinois
- Northwestern University — Chicago
New York
- Universal Dermatology, PLLC — Fairport
Pennsylvania
- University of Pittsburgh Medical Center — Pittsburgh
Texas
- Alpesh D. Desai, DO, PLLC, a Houston company institution — Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,111 participants |
| Start Date | 2022-03-15 |
| Est. Completion | 2022-09-15 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05126173
The ClinicalTrials.gov registry entry for NCT05126173 describes a study currently listed as completed. It is categorized as an unspecified phase, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 1,111 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Skin Analytics Limited, which has 1 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 3 conditions, with Squamous Cell Carcinoma appearing as the primary indexed condition, and to 1 intervention — of which Deep Ensemble for the Recognition of Malignancy (DERM) is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT05126173 reports 16 study locations spanning 9 distinct geographic areas — top geographies include Other, Florida, Massachusetts. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT05126173 about?
NCT05126173 is a clinical study titled "DERM US and EU Validation Study". This study aims establish the effectiveness of Image Analysing Algorithm (DERM) to identify melanoma, Squamous Cell Carcinoma (SCC) and Basal Cell Carcinoma (BCC) when used to analyse dermoscopic images of skin lesions within the US and European population.
What is the current status of trial NCT05126173?
This trial is currently completed. The enrollment target is 1,111 participants. The study started on 2022-03-15. Estimated completion is 2022-09-15.
What conditions does trial NCT05126173 study?
This clinical trial studies the following conditions: Squamous Cell Carcinoma, Basal Cell Carcinoma, Malignant Skin Melanoma T0. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT05126173?
The interventions under investigation include: Deep Ensemble for the Recognition of Malignancy (DERM) (DEVICE). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT05126173?
This trial is sponsored by Skin Analytics Limited, which has 1 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT05126173 being conducted?
This trial has 16 study locations across California, Florida, Illinois, Massachusetts, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.